
FDA Approves AMVUTTRA® an RNAi Therapeutic to Reduce Cardiovascular Death
Alnylam Pharmaceuticals, Inc. announced that the FDA has approved the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA® (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated …